No results for ‘’
Torrent Pharmaceuticals Ltd
₹4429.80
(0.35%)
Fri, 26 Jun 2026, 01:34 am
Health Technology
Pharmaceuticals: Major
24.5KTorrent Pharmaceuticals Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 32.77 | 17.85 | 8.88 | 6.15 | 19.95 | 18.11 | 18.73 | 13.59 | 13.35 | 26.16 | 13.08 | 28.08 | 31.14 | 75.72 | 32.56 | 34.35 | 60.89 | 41.78 | 53.15 | 57.28 |
| Price to book ratio | 5.29 | 4.07 | 2.35 | 1.74 | 5.55 | 4.82 | 4.48 | 4.16 | 4.67 | 7.89 | 6.49 | 6.03 | 4.57 | 6.99 | 6.92 | 7.37 | 7.95 | 8.39 | 12.84 | 14.42 |
| Price to sales ratio | 1.97 | 1.32 | 0.91 | 0.72 | 2.52 | 2.31 | 2.05 | 1.93 | 2.20 | 4.30 | 3.46 | 4.57 | 3.57 | 4.35 | 4.25 | 5.41 | 5.58 | 5.46 | 8.30 | 9.64 |
| Price to cash flow ratio | 83.94 | 29.84 | 5.38 | 4.54 | 16.94 | 12.55 | 10.50 | 37.63 | 15.54 | 31.01 | 8.94 | 31.87 | 33.81 | 25.36 | 36.09 | 25.99 | 30.48 | 25.04 | 30.27 | 46.72 |
| Enterprise value | 2022Cr | 1947Cr | 1443Cr | 1392Cr | 4762Cr | 4880Cr | 5103Cr | 5830Cr | 8968Cr | 21274Cr | 23546Cr | 26759Cr | 26097Cr | 37880Cr | 38536Cr | 47134Cr | 50802Cr | 56672Cr | 91077Cr | 112000Cr |
| Enterprise value to EBITDA ratio | 26.58 | 15.60 | 8.66 | 5.40 | 13.78 | 15.96 | 11.29 | 10.57 | 9.51 | 21.46 | 8.52 | 20.02 | 19.65 | 19.36 | 17.86 | 18.94 | 21 | 20.13 | 27.36 | 30.73 |
| Debt to equity ratio | 0.76 | 0.73 | 0.72 | 0.75 | 0.65 | 0.58 | 0.49 | 0.49 | 0.60 | 1.10 | 0.67 | 0.58 | 1.40 | 1.28 | 1.21 | 0.84 | 0.68 | 0.87 | 0.59 | 0.42 |
| Return on equity % | 16.95 | 24.67 | 29.28 | 31.78 | 31.20 | 29.25 | 25.78 | 33.25 | 40.09 | 34.24 | 57.92 | 23.80 | 15.12 | 9.34 | 21.47 | 23.49 | 13.18 | 20.50 | 25.38 | 26.46 |
Torrent Pharmaceuticals Ltd Enterprise Value
The Torrent Pharmaceuticals Ltd Enterprise Value is a key financial metric used by investors to evaluate Torrent Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Torrent Pharmaceuticals Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM, BSE: 500420) is currently trading at ₹4429.80, with a market capitalization of ₹150360.2Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Torrent Pharmaceuticals Ltd Enterprise Value is essential for fundamental analysis.
Torrent Pharmaceuticals Ltd Enterprise Value Current Value
The current Torrent Pharmaceuticals Ltd Enterprise Value stands at 112000Cr.
The latest Torrent Pharmaceuticals Ltd Enterprise Value has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Torrent Pharmaceuticals Ltd Enterprise Value Historical Trend
The Torrent Pharmaceuticals Ltd Enterprise Value has shown the following historical trend:
- 2024: 112000Cr
- 2023: 91077Cr
- 2022: 56672Cr
- 2021: 50802Cr
- 2020: 47134Cr
The recent rise in Torrent Pharmaceuticals Ltd Enterprise Value suggests strengthening valuation trends and improving market sentiment.
What Torrent Pharmaceuticals Ltd Enterprise Value Indicates for Investors
The Torrent Pharmaceuticals Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals Ltd Enterprise Value Analysis Summary
The Torrent Pharmaceuticals Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Torrent Pharmaceuticals Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Torrent Pharmaceuticals Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.